BioCentury | Jan 22, 2021
Regulation

CAR T Yescarta among new approvals by Japanese regulator

...Adlumiz anamorelin from Helsinn Healthcare S.A.; Lynspad α-1 proteinase inhibitor, known elsewhere as Prolastin-C from Grifols S.A....
...Sciences Inc. Daiichi Pharmaceutical Co. Ltd. Ono Pharmaceutical Co. Ltd. Torii Pharmaceutical Co. Ltd. Takeda Pharmaceutical Co. Ltd. Helsinn Healthcare S.A. Grifols S.A. BioCryst...
BioCentury | Oct 9, 2020
Product Development

COVID-19 Quick Takes: Moderna won’t challenge vaccine IP, wins contract for mobile GMP manufacturing

...Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) study to treat hospitalized COVID-19 patients. Emergent BioSolutions Inc. (NYSE:EBS), Grifols S.A....
...Inc. U.S. Defense Advanced Research Projects Agency Gilead Sciences Inc. The European Commission Johnson & Johnson NIH National Cancer Institute Emergent BioSolutions Inc. Grifols S.A. Takeda...
BioCentury | Sep 9, 2020
Product Development

Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE

...candidates are in Phase I for various cancers.Grifols...
...total of $146 millionSpanish plasma-derived therapy company Grifols S.A....
...a co-development and commercialization deal that gave Grifols...
BioCentury | Mar 26, 2020
Product Development

COVID-19 roundup: Grifols partners with BARDA, FDA on convalescent plasma; plus Vir, Sorrento, Ascletis, BMS and Ipsen

...On the heels of FDA guidance for compassionate use of convalescent plasma for COVID-19, Grifols announced...
...U.S. government to develop the therapy. Meanwhile, Vir and Sorrento are advancing their COVID-19 countermeasures. Grifols S.A....
...the plasma into hyperimmune globulin and support preclinical and clinical studies evaluating the therapy’s efficacy. Grifols...
BioCentury | Aug 5, 2019
Clinical News

Aug. 5 Clinical Quick Takes: Emgality meets for migraine with treatment failures; plus Verona, Alkahest-Grifols, Squarex and Denali-Sanofi

...four scales, the trial's secondary endpoints. The plasma protein fraction, which Alkahest is developing with Grifols S.A....
...Wong, Staff Writer AKST6019 (GRF6019, ALK6019) DNL758 Emgality, galcanezumab-gnlm (LY2951742) ensifentrine (RPL554, VMX554, VRP554) SQX770 Alkahest Inc. Denali Therapeutics Inc. Eli Lilly and Co. Grifols S.A. Sanofi Squarex...
BioCentury | Jan 26, 2019
Product Development

Raising the BD bar

...is already partnered with Grifols S.A. under a 2015 co-development and commercialization deal. Nikolich said that Grifols...
...Summit, N.J. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Grifols S.A....
BioCentury | Dec 14, 2018
Financial News

Moderna raises $604M in record IPO, loses $1.4B in trading debut

...2009; however, unlike Moderna, it had multiple marketed therapies at the time of its listing. Grifols S.A....
BioCentury | Dec 7, 2018
Financial News

Moderna sets IPO record with upsized $604M offering

...2009; however, unlike Moderna, it had multiple marketed therapies at the time of its listing. Grifols S.A....
BioCentury | Nov 30, 2018
Financial News

Moderna proposes terms for record IPO

...million in 2009. That company had multiple marketed therapies at the time of its listing; Grifols S.A....
BioCentury | Nov 28, 2018
Financial News

Moderna proposes terms for record IPO

...million in 2009. That company had multiple marketed therapies at the time of its listing; Grifols S.A....
Items per page:
1 - 10 of 91
BioCentury | Jan 22, 2021
Regulation

CAR T Yescarta among new approvals by Japanese regulator

...Adlumiz anamorelin from Helsinn Healthcare S.A.; Lynspad α-1 proteinase inhibitor, known elsewhere as Prolastin-C from Grifols S.A....
...Sciences Inc. Daiichi Pharmaceutical Co. Ltd. Ono Pharmaceutical Co. Ltd. Torii Pharmaceutical Co. Ltd. Takeda Pharmaceutical Co. Ltd. Helsinn Healthcare S.A. Grifols S.A. BioCryst...
BioCentury | Oct 9, 2020
Product Development

COVID-19 Quick Takes: Moderna won’t challenge vaccine IP, wins contract for mobile GMP manufacturing

...Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) study to treat hospitalized COVID-19 patients. Emergent BioSolutions Inc. (NYSE:EBS), Grifols S.A....
...Inc. U.S. Defense Advanced Research Projects Agency Gilead Sciences Inc. The European Commission Johnson & Johnson NIH National Cancer Institute Emergent BioSolutions Inc. Grifols S.A. Takeda...
BioCentury | Sep 9, 2020
Product Development

Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE

...candidates are in Phase I for various cancers.Grifols...
...total of $146 millionSpanish plasma-derived therapy company Grifols S.A....
...a co-development and commercialization deal that gave Grifols...
BioCentury | Mar 26, 2020
Product Development

COVID-19 roundup: Grifols partners with BARDA, FDA on convalescent plasma; plus Vir, Sorrento, Ascletis, BMS and Ipsen

...On the heels of FDA guidance for compassionate use of convalescent plasma for COVID-19, Grifols announced...
...U.S. government to develop the therapy. Meanwhile, Vir and Sorrento are advancing their COVID-19 countermeasures. Grifols S.A....
...the plasma into hyperimmune globulin and support preclinical and clinical studies evaluating the therapy’s efficacy. Grifols...
BioCentury | Aug 5, 2019
Clinical News

Aug. 5 Clinical Quick Takes: Emgality meets for migraine with treatment failures; plus Verona, Alkahest-Grifols, Squarex and Denali-Sanofi

...four scales, the trial's secondary endpoints. The plasma protein fraction, which Alkahest is developing with Grifols S.A....
...Wong, Staff Writer AKST6019 (GRF6019, ALK6019) DNL758 Emgality, galcanezumab-gnlm (LY2951742) ensifentrine (RPL554, VMX554, VRP554) SQX770 Alkahest Inc. Denali Therapeutics Inc. Eli Lilly and Co. Grifols S.A. Sanofi Squarex...
BioCentury | Jan 26, 2019
Product Development

Raising the BD bar

...is already partnered with Grifols S.A. under a 2015 co-development and commercialization deal. Nikolich said that Grifols...
...Summit, N.J. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Grifols S.A....
BioCentury | Dec 14, 2018
Financial News

Moderna raises $604M in record IPO, loses $1.4B in trading debut

...2009; however, unlike Moderna, it had multiple marketed therapies at the time of its listing. Grifols S.A....
BioCentury | Dec 7, 2018
Financial News

Moderna sets IPO record with upsized $604M offering

...2009; however, unlike Moderna, it had multiple marketed therapies at the time of its listing. Grifols S.A....
BioCentury | Nov 30, 2018
Financial News

Moderna proposes terms for record IPO

...million in 2009. That company had multiple marketed therapies at the time of its listing; Grifols S.A....
BioCentury | Nov 28, 2018
Financial News

Moderna proposes terms for record IPO

...million in 2009. That company had multiple marketed therapies at the time of its listing; Grifols S.A....
Items per page:
1 - 10 of 91